Viewing last 25 versions of post by The Equestrian Zodiac in topic The Virus Outbreak Thread

[Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19](https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/)


[An oral pill for COVID-19? Molnupiravir shows promise](https://www.news-medical.net/news/20210627/An-oral-pill-for-COVID19-Molnupiravir-shows-promise.aspx)

[Science blogger, Derek Lowe, does a breakdown on Molnupiravir ](https://www.science.org/content/blog-post/molnupiravir-thor-s-hammer-delivers)

Latter two links were from this [reddit post](https://www.reddit.com/r/COVID19_support/comments/pz7n58/mercks_pill_cuts_risk_of_death_hospitalization_by/hez2oey/).

"https://www.m[Merck.com/news/merck- and-r Ridgeback’s-i Investigational-o Oral-a Antiviral-m Molnupiravir-r Reduced- the-r Risk- of-h Hospitalization- or-d Death- by-a Approximately- 50-p Percent-c Compared- to-p Placebo- for-p Patients- with-m Mild- or-m Moderat/"e COVID-19](https:M//www.merck .com/news/merck-and R-ridgeback’s I-investigational O-oral A-antiviral M-molnupiravir R-reduced -the R-risk -of H-hospitalization -or D-death -by A-approximately -50 P-percent C-compared -to P-placebo -for P-patients -with M-mild -or M-moderate COVID-19/)

"Mhttps://www.merck .com/news/merck-and R-ridgeback’s I-investigational O-oral A-antiviral M-molnupiravir R-reduced -the R-risk -of H-hospitalization -or D-death -by A-approximately -50 P-percent C-compared -to P-placebo -for P-patients -with M-mild -or M-moderate COVID-19/":https://www.mMerck.com/news/merck- and-r Ridgeback’s-i Investigational-o Oral-a Antiviral-m Molnupiravir-r Reduced- the-r Risk- of-h Hospitalization- or-d Death- by-a Approximately- 50-p Percent-c Compared- to-p Placebo- for-p Patients- with-m Mild- or-m Moderat/e COVID-19